Licensing status

Publication and contact information

Endocrine/metabolic disease


Fatty acid binding protein 4 adipocyte (FABP4)

In vitro and mouse studies suggest blocking FABP4 could help treat diabetes. In primary hepatocytes and in lean mice, recombinant Fabp4 stimulated glucose production and gluconeogenesis. In obese mice, secretion of Fabp4 from adipocytes was greater than that in lean mice, and a neutralizing FABP4-targeting antibody decreased Fabp4 serum levels and increased glucose metabolism and clearance compared with a control antibody. Next steps include developing a humanized mAb targeting FABP4.

SciBX 6(22); doi:10.1038/scibx.2013.547
Published online June 6, 2013

Patent application filed for the use of antibodies targeting FABP4 in diabetes; exclusively licensed to UCB Group

Cao, H. et al. Cell Metab.;
published online May 7, 2013;
Contact: Gökhan S. Hotamisligil, Harvard School of Public Health, Boston, Mass.